drugset
drugset / Trial / NCT03228394

A Clinical Trial of Intravenous (IV) Ganaxolone in Women With Postpartum Depression

NCT03228394 ↗

Phase 2 Completed 91 enrolled Marinus Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the Safety, Pharmacokinetics and Efficacy of IV Administration of Ganaxolone in Women with Postpartum Depression

Timeline

Start
2017-06-27
Primary completion
2019-05-10
Completion
2020-05-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ganaxolone Small molecule — Intravenous

Indications

developmental delay, impaired speech, and behavioral abnormalities postpartum depression pregnancy disorder puerperal disorder